
    
      A Phase 1 open label parallel group, four arm study conducted in healthy male and female
      subject aged 18 to 55 years of age. Subjects will receive either treatment A, B, C or D as
      described below:

        -  Treatment A: 1440 mg PQP tablets and 800 mg OZ439 + TPGS granules for oral suspension

        -  Treatment B: 960 mg PQP tablets and 800 mg OZ439 + TPGS granules for oral suspension

        -  Treatment C: 960 mg PQP granules for oral solution and 800 mg OZ439 + TPGS granules for
           oral suspension

        -  Treatment D: 800 mg OZ439 + TPGS granules for oral suspension
    
  